EUCTR2009-017798-39-IT进行中（未招募）不适用
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - ND
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2010年6月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Aged 18 years or older
- •2.Histological or cytological confirmation of prostate adenocarcinoma
- •3.Biochemical recurrence after potentially curative standard therapies for localized disease or Biochemical progression while the patient has castrate levels of testosterone (Castration resistant prostate cancer) or patients with progression after first-line anti hormonal treatment
- •4. Negative bone scan (performed no more than 90 days prior enrollment)
- •5.HLA A1, A2, A3, A24 or B7 as assessed by HLA Genotyping
- •6.ECOG Performance status 0 or 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Active malignancy other than prostate cancer
- •2.Clinical evidence of metastatic disease, local recurrence of pelvic lymph node disease
- •3.PSA > 10 ng/ml
- •4.History of past or current autoimmune disease or primary or secondary immunodeficiencies
- •5.Known hypersensitivity to any component of trial treatment
研究者
相似试验
进行中（未招募）
不适用
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.nresectable and progressive metastatic cutaneous melanomaMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2004-001937-40-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER68
进行中（未招募）
1 期
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanomanresectable and progressive metastatic cutaneous melanomaMedDRA version: 7.0Level: LLTClassification code 10027155EUCTR2004-001937-40-ESEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
不适用
Safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib (Infanrix-IPV/Hib) in infants.Healthy volunteers (Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases).EUCTR2015-001513-27-Outside-EU/EEAGlaxoSmithKline Biologicals50
进行中（未招募）
1 期
Aditec Flu 2 Study: Understanding the genetic basis for immune responses to flu vaccines in children and adultsThis trial is investigating healthy children and adult's gene expression and immune response to the Fluad (MF59)-adjuvanted trivalent influenza vaccine and also comparing these to the local and general reactions following vaccine administration. Healthy children will be immunised with 2 doses, adult with 1 dose.EUCTR2015-001648-12-GBniversity of Oxford120
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40